BIOTECHNOLOGY
SYSTEMS
BRANCH



SK

RAW SEQUENCE LISTING ERROR REPORT

The Biotechnology Systems Branch of the Scientific and Technical Information Center (STIC) detected errors when processing the following computer readable form:

Application Serial Number: 09/701,623B

Source: PCT/09

Date Processed by STIC: 9/20/2001

THE ATTACHED PRINTOUT EXPLAINS DETECTED ERRORS.
PLEASE FORWARD THIS INFORMATION TO THE APPLICANT BY EITHER:

1) **INCLUDING A COPY OF THIS PRINTOUT IN YOUR NEXT COMMUNICATION TO THE APPLICANT, WITH A NOTICE TO COMPLY or,**
2) **TELEPHONING APPLICANT AND FAXING A COPY OF THIS PRINTOUT, WITH A NOTICE TO COMPLY**

FOR CRF SUBMISSION QUESTIONS, PLEASE CONTACT MARK SPENCER, 703-308-4212.

FOR SEQUENCE RULES INTERPRETATION, PLEASE CONTACT ROBERT WAX, 703-308-4216.
PATENTIN 2.1 e-mail help: patin21help@uspto.gov or phone 703-306-4119 (R. Wax)
PATENTIN 3.0 e-mail help: patin3help@uspto.gov or phone 703-306-4119 (R. Wax)

TO **REDUCE** ERRORED SEQUENCE LISTINGS, **PLEASE** USE THE **CHECKER VERSION 3.0 PROGRAM**, ACCESSIBLE THROUGH THE U.S. PATENT AND TRADEMARK OFFICE WEBSITE. SEE BELOW:

Checker Version 3.0

The Checker Version 3.0 application is a state-of the-art Windows based software program employing a logical and intuitive user-interface to check whether a sequence listing is in compliance with format and content rules. Checker Version 3.0 works for sequence listings generated for the original version of 37 CFR §§1.821 – 1.825 effective October 1, 1990 (old rules) and the revised version (new rules) effective July 1, 1998 as well as World Intellectual Property Organization (WIPO) Standard ST.25.
Checker Version 3.0 replaces the previous DOS-based version of Checker, and is Y2K-compliant. Checker allows public users to check sequence listings in Computer Readable form (CRF) before submitting them to the United States Patent and Trademark Office (USPTO). Use of Checker prior to filing the sequence listing is expected to result in fewer errored sequence listings, thus saving time and money.

Checker Version 3.0 can be down loaded from the USPTO website at the following address:

http://www.uspto.gov/web/offices/pac/checker

Raw Sequence Listing Error Summary

ERROR DETECTED | SUGGESTED CORRECTION | SERIAL NUMBER: 09/901,623B

ATTN: NEW RULES CASES: PLEASE DISREGARD ENGLISH "ALPHA" HEADERS, WHICH WERE INSERTED BY PTO SOFTWARE

1____ Wrapped Nucleics / Wrapped Aminos — The number/text at the end of each line "wrapped" down to the next line. This may occur if your file was retrieved in a word processor after creating it. Please adjust your right margin to .3; this will prevent "wrapping."

2____ Invalid Line Length — The rules require that a line not exceed 72 characters in length. This includes white spaces.

3____ Misaligned Amino Numbering — The numbering under each 5th amino acid is misaligned. Do not use tab codes between numbers; use space characters, instead.

4____ Non-ASCII — The submitted file was not saved in ASCII(DOS) text, as required by the Sequence Rules. Please ensure your subsequent submission is saved in ASCII text.

5____ Variable Length — Sequence(s)____contain n's or Xaa's representing more than one residue. Per Sequence Rules, each n or Xaa can only represent a single residue. Please present the maximum number of each residue having variable length and indicate in the <220>-<223> section that some may be missing.

6____ PatentIn 2.0 "bug" — A "bug" in PatentIn version 2.0 has caused the <220>-<223> section to be missing from amino acid sequences(s) _____. Normally, PatentIn would automatically generate this section from the previously coded nucleic acid sequence. Please manually copy the relevant <220>-<223> section to the subsequent amino acid sequence. This applies to the mandatory <220>-<223> sections for Artificial or Unknown sequences.

7____ Skipped Sequences (OLD RULES) — Sequence(s) _____ missing. If intentional, please insert the following lines for each skipped sequence:
(2) INFORMATION FOR SEQ ID NO:X: (insert SEQ ID NO where "X" is shown)
(i) SEQUENCE CHARACTERISTICS: (Do not insert any subheadings under this heading)
(xi) SEQUENCE DESCRIPTION:SEQ ID NO:X: (insert SEQ ID NO where "X" is shown)
This sequence is intentionally skipped

Please also adjust the "(ii) NUMBER OF SEQUENCES:" response to include the skipped sequences.

8____ Skipped Sequences (NEW RULES) — Sequence(s) _____ missing. If intentional, please insert the following lines for each skipped sequence.
<210> sequence id number
<400> sequence id number
000

9____ Use of n's or Xaa's (NEW RULES) — Use of n's and/or Xaa's have been detected in the Sequence Listing.
Per 1.823 of Sequence Rules, use of <220>-<223> is MANDATORY if n's or Xaa's are present.
In <220> to <223> section, please explain location of n or Xaa, and which residue n or Xaa represents.

10____ Invalid <213> Response — Per 1.823 of Sequence Rules, the only valid <213> responses are: Unknown, Artificial Sequence, or scientific name (Genus/species). <220>-<223> section is required when <213> response is Unknown or is Artificial Sequence

11____ Use of <220> — Sequence(s) _____ missing the <220> "Feature" and associated numeric identifiers and responses.
Use of <220> to <223> is MANDATORY if <213> "Organism" response is "Artificial Sequence" or "Unknown." Please explain source of genetic material in <220> to <223> section.
(See "Federal Register," 06/01/1998, Vol. 63, No. 104, pp. 29631-32) (Sec. 1.823 of Sequence Rules)

12____ PatentIn 2.0 "bug" — Please do not use "Copy to Disk" function of PatentIn version 2.0. This causes a corrupted file, resulting in missing mandatory numeric identifiers and responses (as indicated on raw sequence listing). Instead, please use "File Manager" or any other manual means to copy file to floppy disk.

13____ Misuse of n — n can only be used to represent a single nucleotide in a nucleic acid sequence. N is not used to represent any value not specifically a nucleotide.

PCT09

RAW SEQUENCE LISTING DATE: 09/20/2001
PATENT APPLICATION: US/09/701,623B TIME: 08:41:20

Input Set : A:\11514153.app
Output Set: N:\CRF3\09202001\I701623B.raw

Does Not Comply
Corrected Diskette Needed

```
 3 <110> APPLICANT: UNITED BIOMEDICAL INC., ET AL.
 5 <120> TITLE OF INVENTION: PEPTIDE COMPOSITION AS IMMUNOGEN FOR THE TREATMENT OF
 6       ALLERGY
 8 <130> FILE REFERENCE: 11514153US1
10 <140> CURRENT APPLICATION NUMBER: 09/701,623B
11 <141> CURRENT FILING DATE: 2000-12-01
13 <150> PRIOR APPLICATION NUMBER: PCT/US99/13959
14 <151> PRIOR FILING DATE: 1999-06-21
16 <150> PRIOR APPLICATION NUMBER: 09/100,287
17 <151> PRIOR FILING DATE: 1998-06-20
19 <160> NUMBER OF SEQ ID NOS: 91
21 <170> SOFTWARE: PatentIn Ver. 2.1
23 <210> SEQ ID NO: 1
24 <211> LENGTH: 325
25 <212> TYPE: PRT
26 <213> ORGANISM: HUMAN
28 <220> FEATURE:
29 <223> OTHER INFORMATION: CH2CH3 of human IgE
31 <300> PUBLICATION INFORMATION:
32 <301> AUTHORs: Dorrington,
33       Bennich,
34 <303> JOURNAL: Immunology
35 <304> VOLUME: 41
36 <306> PAGES: 3-25
37 <307> DATE: 1978
39 <400> SEQUENCE: 1
40 Val Cys Ser Arg Asp Phe Thr Pro Pro Thr Val Lys Ile Leu Gln Ser
41   1               5                  10                  15
43 Ser Cys Asp Gly Gly Gly His Phe Pro Pro Thr Ile Gln Leu Leu Cys
44              20                  25                  30
46 Leu Val Ser Gly Tyr Thr Pro Gly Thr Ile Asn Ile Thr Trp Leu Glu
47          35                  40                  45
49 Asp Gly Gln Val Met Asp Val Asp Leu Ser Thr Ala Ser Thr Thr Gln
50      50                  55                  60
52 Glu Gly Glu Leu Ala Ser Thr Gln Ser Glu Leu Thr Leu Ser Gln Lys
53  65                  70                  75                  80
55 His Trp Leu Ser Asp Arg Thr Tyr Thr Cys Gln Val Thr Tyr Gln Gly
56                  85                  90                  95
58 His Thr Phe Glu Asp Ser Thr Lys Lys Cys Ala Asp Ser Asn Pro Arg
59              100                 105                 110
61 Gly Val Ser Ala Tyr Leu Ser Arg Pro Ser Pro Phe Asp Leu Phe Ile
62          115                 120                 125
64 Arg Lys Ser Pro Thr Ile Thr Cys Leu Val Val Asp Leu Ala Pro Ser
65      130                 135                 140
67 Lys Gly Thr Val Asn Leu Thr Trp Ser Arg Ala Ser Gly Lys Pro Val
68 145                 150                 155                 160
70 Asn His Ser Thr Arg Lys Glu Glu Lys Gln Arg Asn Gly Thr Leu Thr
```

RAW SEQUENCE LISTING DATE: 09/20/2001
PATENT APPLICATION: US/09/701,623B TIME: 08:41:20

Input Set : A:\11514153.app
Output Set: N:\CRF3\09202001\I701623B.raw

```
71                 165                 170                 175
73 Val Thr Ser Thr Leu Pro Val Gly Thr Arg Asp Trp Ile Glu Gly Glu
74             180                 185                 190
76 Thr Tyr Gln Cys Arg Val Thr His Pro His Leu Pro Arg Ala Leu Met
77         195                 200                 205
79 Arg Ser Thr Thr Lys Thr Ser Gly Pro Arg Ala Ala Pro Glu Val Tyr
80     210                 215                 220
82 Ala Phe Ala Thr Pro Glu Trp Pro Gly Ser Arg Asp Lys Arg Thr Leu
83 225                 230                 235                 240
85 Ala Cys Leu Ile Gln Asn Phe Met Pro Glu Asp Ile Ser Val Gln Trp
86                 245                 250                 255
88 Leu His Asn Glu Val Gln Leu Pro Asp Ala Arg His Ser Thr Thr Gln
89             260                 265                 270
91 Pro Arg Lys Thr Lys Gly Ser Gly Phe Phe Val Phe Ser Arg Leu Glu
92         275                 280                 285
94 Val Thr Arg Ala Glu Trp Gln Glu Lys Asp Glu Phe Ile Cys Arg Ala
95     290                 295                 300
97 Val His Glu Ala Ala Ser Pro Ser Gln Thr Val Gln Arg Ala Val Ser
98 305                 310                 315                 320
100 Val Asn Pro Gly Lys
101                 325
104 <210> SEQ ID NO: 2
105 <211> LENGTH: 312
106 <212> TYPE: PRT
107 <213> ORGANISM: Dog
109 <220> FEATURE:
110 <223> OTHER INFORMATION: CH2CH3n of dog IgE
112 <300> PUBLICATION INFORMATION:
113 <301> AUTHORs: Patel,
114 <303> JOURNAL: Immunogenetics
115 <304> VOLUME: 41
116 <306> PAGES: 282-286
117 <307> DATE: 1995
119 <400> SEQUENCE: 2
120 Ala Cys Ala Leu Asn Phe Ile Pro Pro Thr Val Lys Leu Phe His Ser
121   1               5                  10                  15
123 Ser Cys Asn Pro Val Gly Asp Thr His Thr Thr Ile Gln Leu Leu Cys
124              20                  25                  30
126 Leu Ile Ser Gly Tyr Val Pro Gly Asp Met Glu Val Ile Trp Leu Val
127          35                  40                  45
129 Asp Gly Gln Lys Ala Thr Asn Ile Phe Pro Tyr Thr Ala Pro Gly Thr
130      50                  55                  60
132 Lys Glu Gly Asn Val Thr Ser Thr His Ser Glu Leu Asn Ile Thr Gln
133  65                  70                  75                  80
135 Gly Glu Trp Val Ser Gln Lys Thr Tyr Thr Cys Gln Gly Phe Thr Phe
136                  85                  90                  95
138 Lys Asp Glu Ala Arg Lys Cys Ser Glu Ser Asp Pro Arg Gly Val Thr
139             100                 105                 110
141 Ser Tyr Leu Ser Pro Pro Ser Pro Leu Asp Leu Tyr Val His Lys Ala
```

RAW SEQUENCE LISTING DATE: 09/20/2001
PATENT APPLICATION: US/09/701,623B TIME: 08:41:20

Input Set : A:\11514153.app
Output Set: N:\CRF3\09202001\I701623B.raw

```
142         115                 120                 125
144 Pro Lys Ile Thr Cys Leu Val Val Asp Leu Ala Thr Met Glu Gly Met
145     130                 135                 140
147 Asn Leu Thr Trp Tyr Arg Glu Ser Lys Glu Pro Val Asn Pro Gly Pro
148 145                 150                 155                 160
150 Leu Asn Lys Lys Asp His Phe Asn Gly Thr Ile Thr Val Thr Ser Thr
151                 165                 170                 175
153 Leu Pro Val Asn Thr Asn Asp Trp Ile Glu Gly Glu Thr Tyr Tyr Cys
154             180                 185                 190
156 Arg Val Thr His Pro His Leu Pro Lys Asp Ile Val Arg Ser Ile Ala
157         195                 200                 205
159 Lys Ala Pro Gly Lys Arg Ala Pro Pro Asp Val Tyr Leu Phe Leu Pro
160     210                 215                 220
162 Pro Glu Glu Glu Gln Gly Thr Lys Asp Arg Val Thr Leu Thr Cys Leu
163 225                 230                 235                 240
165 Ile Gln Asn Phe Phe Pro Ala Asp Ile Ser Val Gln Trp Leu Arg Asn
166                 245                 250                 255
168 Asp Ser Pro Ile Gln Thr Asp Gln Tyr Thr Thr Thr Gly Pro His Lys
169             260                 265                 270
171 Val Ser Gly Ser Arg Pro Ala Phe Phe Ile Phe Ser Arg Leu Glu Val
172         275                 280                 285
174 Ser Arg Val Asp Trp Glu Gln Lys Asn Lys Phe Thr Cys Gln Val Val
175     290                 295                 300
177 His Glu Ala Leu Ser Gly Ser Arg
178 305                 310
181 <210> SEQ ID NO: 3
182 <211> LENGTH: 313
183 <212> TYPE: PRT
184 <213> ORGANISM: RAT
186 <220> FEATURE:
187 <223> OTHER INFORMATION: CH2CH3 of rat IgE
189 <300> PUBLICATION INFORMATION:
190 <301> AUTHORs: Dorrington,
191       Bennich,
192 <303> JOURNAL: Immunology
193 <304> VOLUME: 41
194 <306> PAGES: 3-25
195 <307> DATE: 1978
197 <300> PUBLICATION INFORMATION:
198 <301> AUTHORs: Patel,
199 <303> JOURNAL: Immunogenetics
200 <304> VOLUME: 41
201 <306> PAGES: 282-286
202 <307> DATE: 1995
204 <300> PUBLICATION INFORMATION:
205 <301> AUTHORs: Steen,
206 <303> JOURNAL: J. Mol. Biol.
207 <304> VOLUME: 177
208 <306> PAGES: 19-32
```

RAW SEQUENCE LISTING DATE: 09/20/2001
PATENT APPLICATION: US/09/701,623B TIME: 08:41:20

Input Set : A:\11514153.app
Output Set: N:\CRF3\09202001\I701623B.raw

<307> DATE: 1984
<300> PUBLICATION INFORMATION:
<301> AUTHORs: Ishida,
<303> JOURNAL: EMBO J.
<304> VOLUME: 1
<306> PAGES: 1117-1123
<307> DATE: 1982
<400> SEQUENCE: 3

```
Ala Arg Pro Val Asn Ile Thr Lys Pro Thr Val Asp Leu Leu His Ser
 1               5                  10                  15
Ser Cys Asp Pro Asn Ala Phe His Ser Thr Ile Gln Leu Tyr Cys Phe
            20                  25                  30
Val Tyr Gly His Ile Gln Asn Asp Val Ser Ile His Trp Leu Met Asp
        35                  40                  45
Asp Arg Lys Ile Tyr Asp Thr His Ala Gln Asn Val Leu Ile Lys Glu
    50                  55                  60
Glu Gly Lys Leu Ala Ser Thr Tyr Ser Arg Leu Asn Ile Thr Gln Gln
65                  70                  75                  80
Gln Trp Met Ser Glu Ser Thr Phe Thr Cys Lys Val Thr Ser Gln Gly
                85                  90                  95
Glu Asn Tyr Trp Ala His Thr Arg Arg Cys Ser Asp Asp Glu Pro Arg
            100                 105                 110
Gly Val Ile Thr Tyr Leu Ile Pro Pro Ser Pro Leu Asp Leu Tyr Glu
        115                 120                 125
Asn Gly Thr Pro Lys Leu Thr Cys Leu Val Leu Asp Leu Glu Ser Glu
    130                 135                 140
Glu Asn Ile Thr Val Thr Trp Val Arg Glu Arg Lys Lys Ser Ile Gly
145                 150                 155                 160
Ser Ala Ser Gln Arg Ser Thr Lys His His Asn Ala Thr Thr Ser Ile
                165                 170                 175
Thr Ser Ile Leu Pro Val Asp Ala Lys Asp Trp Ile Glu Gly Glu Gly
            180                 185                 190
Tyr Gln Cys Arg Val Asp His Pro His Phe Pro Lys Pro Ile Val Arg
        195                 200                 205
Ser Ile Thr Lys Ala Leu Gly Leu Arg Ser Ala Pro Glu Val Tyr Val
    210                 215                 220
Phe Leu Pro Pro Glu Glu Glu Glu Lys Asn Lys Arg Thr Leu Thr Cys
225                 230                 235                 240
Leu Ile Gln Asn Phe Phe Pro Glu Asp Ile Ser Val Gln Trp Leu Gln
                245                 250                 255
Asp Ser Lys Leu Ile Pro Lys Ser Gln His Ser Thr Thr Thr Pro Leu
            260                 265                 270
Lys Thr Asn Gly Ser Asn Gln Arg Phe Phe Ile Phe Ser Arg Leu Glu
        275                 280                 285
Val Thr Lys Ala Leu Trp Thr Gln Thr Lys Gln Phe Thr Cys Arg Val
    290                 295                 300
Ile His Glu Ala Leu Arg Glu Pro Arg
305                 310
```

<210> SEQ ID NO: 4

RAW SEQUENCE LISTING DATE: 09/20/2001
PATENT APPLICATION: US/09/701,623B TIME: 08:41:20

Input Set : A:\11514153.app
Output Set: N:\CRF3\09202001\I701623B.raw

```
281 <211> LENGTH: 313
282 <212> TYPE: PRT
283 <213> ORGANISM: Artificial Sequence
285 <220> FEATURE:
286 <223> OTHER INFORMATION: CH2CH3 of mouse IgE
288 <400> SEQUENCE: 4
289 Val Arg Pro Val Thr His Ser Leu Ser Pro Pro Trp Ser Tyr Ser Ile
290   1               5                  10                  15
292 His Arg Cys Asp Pro Asn Ala Phe His Ser Thr Ile Gln Leu Tyr Cys
293              20                  25                  30
295 Phe Ile Tyr Gly His Ile Leu Asn Asp Val Ser Val Ser Trp Leu Met
296          35                  40                  45
298 Asp Asp Arg Glu Ile Thr Asp Thr Leu Ala Gln Thr Val Leu Ile Lys
299      50                  55                  60
301 Glu Glu Gly Lys Leu Ala Ser Thr Cys Ser Lys Leu Asn Ile Thr Glu
302  65                  70                  75                  80
304 Gln Gln Trp Met Ser Glu Ser Thr Phe Thr Cys Arg Val Thr Ser Gln
305                  85                  90                  95
307 Gly Cys Asp Tyr Leu Ala His Thr Arg Arg Cys Pro Asp His Glu Pro
308             100                 105                 110
310 Arg Gly Ala Ile Thr Tyr Leu Ile Pro Pro Ser Pro Leu Asp Leu Tyr
311         115                 120                 125
313 Gln Asn Gly Ala Pro Lys Leu Thr Cys Leu Val Val Asp Leu Glu Ser
314     130                 135                 140
316 Glu Lys Asn Val Asn Val Thr Trp Asn Gln Glu Lys Lys Thr Ser Val
317 145                 150                 155                 160
319 Ser Ala Ser Gln Trp Tyr Thr Lys His His Asn Asn Ala Thr Thr Ser
320                 165                 170                 175
322 Ile Thr Ser Ile Leu Pro Val Val Ala Lys Asp Trp Ile Glu Gly Tyr
323             180                 185                 190
325 Gly Tyr Gln Cys Ile Val Asp Arg Pro Asp Phe Pro Lys Pro Ile Val
326         195                 200                 205
328 Arg Ser Ile Thr Lys Thr Pro Gly Gln Arg Ser Ala Pro Glu Val Tyr
329     210                 215                 220
331 Val Phe Pro Pro Pro Glu Glu Glu Ser Glu Asp Lys Arg Thr Leu Thr
332 225                 230                 235                 240
334 Cys Leu Ile Gln Asn Phe Phe Pro Glu Asp Ile Ser Val Gln Trp Leu
335                 245                 250                 255
337 Gly Asp Gly Lys Leu Ile Ser Asn Ser Gln His Ser Thr Thr Thr Pro
338             260                 265                 270
340 Leu Lys Ser Asn Gly Asn Gln Gly Phe Phe Ile Phe Ser Arg Leu Glu
341         275                 280                 285
343 Val Ala Lys Thr Leu Trp Thr Gln Arg Lys Gln Phe Thr Cys Gln Val
344     290                 295                 300
346 Ile His Glu Ala Leu Gln Lys Pro Arg
347 305                 310
350 <210> SEQ ID NO: 5
351 <211> LENGTH: 25
352 <212> TYPE: PRT
```

<210> SEQ ID NO 16
<211> LENGTH: 6
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: peptide
<400> SEQUENCE: 16
Pro Pro Xaa Pro Xaa Pro
1 5

insufficient explanation - give source of genetic material - see item 11 on Error Summary Sheet

see item 9 on Error Summary Sheet

Use of n and/or Xaa has been detected in the Sequence Listing.
Review the Sequence Listing to insure a corresponding explanation is presented in the <220> to <223> fields of each sequence using n or Xaa.

VERIFICATION SUMMARY DATE: 09/20/2001
PATENT APPLICATION: **US/09/701,623B** TIME: 08:41:21

Input Set : **A:\11514153.app**
Output Set: **N:\CRF3\09202001\I701623B.raw**

L:488 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:10
L:546 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:11
L:549 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:11
L:629 M:258 W: Mandatory Feature missing, <221> not found for SEQ ID#:16
L:629 M:258 W: Mandatory Feature missing, <222> not found for SEQ ID#:16
L:629 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:16
L:694 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:18
L:746 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:19
L:749 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:19
L:798 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:20
L:862 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:21
L:929 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:22
L:932 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:22
L:993 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:23
L:996 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:23
L:1045 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:24
L:1157 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:27
L:1160 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:27
L:1198 M:258 W: Mandatory Feature missing, <221> not found for SEQ ID#:29
L:1198 M:258 W: Mandatory Feature missing, <222> not found for SEQ ID#:29
L:1198 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:29
L:1769 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:60
L:2193 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:85